NRX Pharmaceuticals vs Rani Therapeutics
Rani Therapeutics reported revenue of $2 million in fiscal 2025, 1.3 times NRX Pharmaceuticals' $1 million in fiscal 2025. NRX Pharmaceuticals had an operating margin of -1324.4%, against -2346.0% at Rani Therapeutics.
Side by side
| NRX Pharmaceuticals | Rani Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1M | $2M |
| Revenue growth | — | 58.9% |
| Revenue growth a year, last 5 years | — | 26.2% |
| Gross margin | 58.8% | — |
| Operating margin | −1,324.4% | −2,346.0% |
| Net margin | −2,336.5% | −1,817.1% |
| Free cash flow | — | −$19M |
| Free cash flow margin | — | −1,151.4% |
| Return on capital | — | −127.1% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 101.1% | 132.3% |
| Last close | $2.55 | $0.58 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | bought $50,040, sold $301 |
| Piotroski F-score | — | 4 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
NRX PharmaceuticalsRani Therapeutics
Operating margin
Percent of revenue
NRX PharmaceuticalsRani Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
NRX PharmaceuticalsRani Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the NRX Pharmaceuticals and Rani Therapeutics pages.